<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02243553</url>
  </required_header>
  <id_info>
    <org_study_id>1182.101</org_study_id>
    <nct_id>NCT02243553</nct_id>
  </id_info>
  <brief_title>Effects of Tipranavir (With Ritonavir) Capsule and Liquid Formulation on Cytochrome P450 and P-glycoprotein Activity in Healthy Volunteers</brief_title>
  <official_title>Evaluating the Effects of Tipranavir (With Ritonavir) Capsule and Liquid Formulation on Cytochrome P450 and P-glycoprotein Activity Using a Biomarker Cocktail in Healthy Human Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      Primary: To quantify the influence of single-dose and steady-state tipranavir/ritonavir
      500/200 mg on intestinal and hepatic cytochrome P450 (CYP) and P-glycoprotein (P-gp)
      biomarkers, as a means of predicting drug interactions. The AUCs for biomarkers caffeine,
      warfarin, omeprazole, dextromethorphan, midazolam, and digoxin will be assessed.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2006</start_date>
  <primary_completion_date type="Actual">July 2006</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under plasma concentration-time curve (AUC) at steady state</measure>
    <time_frame>up to 72 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration after 12 hours (Cp12h)</measure>
    <time_frame>12 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum plasma concentration (Cmax)</measure>
    <time_frame>up to 12 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of maximum concentration (Tmax)</measure>
    <time_frame>up to 72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent terminal half-life (t1/2)</measure>
    <time_frame>up to 72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under plasma concentration-time curve (AUC) after single dose</measure>
    <time_frame>up to 72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in biomarkers</measure>
    <time_frame>baseline, up to 22 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in enzyme activity</measure>
    <time_frame>baseline, up to 22 days</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Treatment A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>tipranavir (TPV) capsule + ritonavir (RTV) capsule + cocktail + digoxin oral</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TPV capsule + RTV capsule + cocktail + digoxin injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TPV solution + RTV capsule + cocktail + digoxin oral</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TPV solution + RTV capsule + cocktail + digoxin injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tipranavir capsule</intervention_name>
    <arm_group_label>Treatment A</arm_group_label>
    <arm_group_label>Treatment B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tipranavir solution</intervention_name>
    <arm_group_label>Treatment C</arm_group_label>
    <arm_group_label>Treatment D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ritonavir capsule</intervention_name>
    <arm_group_label>Treatment A</arm_group_label>
    <arm_group_label>Treatment B</arm_group_label>
    <arm_group_label>Treatment C</arm_group_label>
    <arm_group_label>Treatment D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Caffeine</intervention_name>
    <arm_group_label>Treatment A</arm_group_label>
    <arm_group_label>Treatment B</arm_group_label>
    <arm_group_label>Treatment C</arm_group_label>
    <arm_group_label>Treatment D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Warfarin sodium</intervention_name>
    <arm_group_label>Treatment A</arm_group_label>
    <arm_group_label>Treatment B</arm_group_label>
    <arm_group_label>Treatment C</arm_group_label>
    <arm_group_label>Treatment D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vitamin K</intervention_name>
    <arm_group_label>Treatment A</arm_group_label>
    <arm_group_label>Treatment B</arm_group_label>
    <arm_group_label>Treatment C</arm_group_label>
    <arm_group_label>Treatment D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omeprazole</intervention_name>
    <arm_group_label>Treatment A</arm_group_label>
    <arm_group_label>Treatment B</arm_group_label>
    <arm_group_label>Treatment C</arm_group_label>
    <arm_group_label>Treatment D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dextromethorphan hydrobromide</intervention_name>
    <arm_group_label>Treatment A</arm_group_label>
    <arm_group_label>Treatment B</arm_group_label>
    <arm_group_label>Treatment C</arm_group_label>
    <arm_group_label>Treatment D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Midazolam injection</intervention_name>
    <arm_group_label>Treatment A</arm_group_label>
    <arm_group_label>Treatment B</arm_group_label>
    <arm_group_label>Treatment C</arm_group_label>
    <arm_group_label>Treatment D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Midazolam oral solution</intervention_name>
    <arm_group_label>Treatment A</arm_group_label>
    <arm_group_label>Treatment B</arm_group_label>
    <arm_group_label>Treatment C</arm_group_label>
    <arm_group_label>Treatment D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Digoxin tablet</intervention_name>
    <arm_group_label>Treatment A</arm_group_label>
    <arm_group_label>Treatment C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Digoxin injection</intervention_name>
    <arm_group_label>Treatment B</arm_group_label>
    <arm_group_label>Treatment D</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Signed informed consent

          2. Healthy subjects aged between 18 years and 45 years inclusive

          3. Weighing at least 50 kg

          4. Volunteers must be hospitalized on Days 1-4, 7-9, and 17-20 for pharmacokinetic
             assessments for each biomarker and TPV/r (Days 7-9 and 17-20)

          5. Volunteers must be willing to complete all study-related activities

          6. Each volunteer must have a valid social security number

          7. Each volunteer must have acceptable medical history, physical examination and
             laboratory test

        Exclusion Criteria:

          1. History or presence of allergy to the study drugs or their components or drugs of
             their class, or a history of drug or other allergy that, in the opinion of the
             physician responsible, contraindicates their participation

          2. Any finding of the medical examination (including blood pressure, pulse rate and
             electrocardiogram) deviating from normal and of clinical relevance

          3. History or diagnosis of any significant medical conditions: Including but not limited
             to gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic,
             immunologic, hematological, psychiatric, neurological, oncological or hormonal
             disorders

          4. Known elevated liver enzymes in past clinical trials with any compound (experimental
             or marketed)

          5. Clinically relevant laboratory abnormalities (e.g. Hgb&lt;11g/dL, Hct&lt;30g/dL, total
             cholesterol &gt;240mg/dL, triglycerides &gt;500mg/dL, fasting glucose &gt;130mg/dL, liver
             function tests &gt;2.5x upper limit of normal, baseline international normalized ratio
             &gt;1.2)

          6. History of evidence of clinically significant hepatic, cardiac, pulmonary, endocrine,
             immunological, gastrointestinal, hematological, vascular or collagen disease

          7. History of alcohol abuse or use of any illicit drugs

          8. Unable to abstain from more than one beer or alcohol equivalent per day for the
             duration of the study

          9. Use of tobacco products and/or history of smoking within the past 2 months

         10. Pregnant or breast feeding

         11. Sexually active women of childbearing age who do not use an acceptable barrier method
             of birth control

         12. Hypersensitivity to caffeine, warfarin, vitamin K, omeprazole, dextromethorphan,
             midazolam, tipranavir, ritonavir or their excipients

         13. Concomitant treatment with other experimental compounds

         14. Concomitant administration of any prescription or over the counter medications known
             to alter P450 enzyme or P-gp activity

         15. Concomitant administration of any prescription or over the counter medications known
             to be highly dependent on P450 or P-gp for clearance for which elevated plasma
             concentrations are known to be associated with serious toxicity

         16. Concomitant administration of any food product known to alter P450 enzyme or P-gp
             activity such as grapefruit juice, Seville oranges

         17. Concomitant administration of any drug that could affect bleeding (e.g., aspirin,
             clopidogrel, ticlopidine, warfarin, heparin, low-molecular weight heparin)

         18. Concomitant administration of oral contraceptives (may be included with 7-day washout
             period)

         19. Concomitant administration of any herbal medications

         20. Inadequate venous access

         21. Renal or hepatic insufficiency

         22. Clinically unacceptable result at the screening physical examination

         23. Use of investigational medications within 30 days before study entry

         24. HIV-positive

         25. Body Mass Index (BMI) &gt; 30 kg/mÂ²
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <link>
    <url>http://trials.boehringer-ingelheim.com</url>
  </link>
  <verification_date>August 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 1, 2014</study_first_submitted>
  <study_first_submitted_qc>September 16, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 18, 2014</study_first_posted>
  <last_update_submitted>September 16, 2014</last_update_submitted>
  <last_update_submitted_qc>September 16, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 18, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Tipranavir</mesh_term>
    <mesh_term>Krestin</mesh_term>
    <mesh_term>Caffeine</mesh_term>
    <mesh_term>Omeprazole</mesh_term>
    <mesh_term>Digoxin</mesh_term>
    <mesh_term>Midazolam</mesh_term>
    <mesh_term>Dextromethorphan</mesh_term>
    <mesh_term>Warfarin</mesh_term>
    <mesh_term>Vitamin K</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

